Published in Perit Dial Int on November 22, 2004
Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein. J Biol Chem (2008) 1.08
Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J (2011) 1.06
Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol (2007) 0.96
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. BMC Cardiovasc Disord (2016) 0.84
Lipoprotein metabolism and CKD: overview. Clin Exp Nephrol (2013) 0.78
Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res (2009) 0.78
Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies: A Randomized, Controlled, Clinical Trial. Medicine (Baltimore) (2016) 0.75
Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA (2012) 9.37
Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int (2004) 2.30
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation (2004) 1.91
The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ (2002) 1.67
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther (2006) 1.52
Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol (2008) 1.46
Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis (2006) 1.44
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord (2012) 1.44
New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol (2007) 1.42
Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int (2006) 1.42
Unexplained hypertransaminasaemia: clue to diagnosis of Addison's disease. Eur J Gastroenterol Hepatol (2002) 1.40
Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid (2003) 1.40
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin (2011) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
α-Defensins and hsCRP levels in inflammatory response of standard and laparoendoscopic single-site cholecystectomy. Surg Endosc (2011) 1.38
The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta (2009) 1.26
Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed (2008) 1.25
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs (2010) 1.18
An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther (2008) 1.16
The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol (2010) 1.14
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis (2006) 1.12
Metformin and cancer. Eur J Pharmacol (2013) 1.11
Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia (2015) 1.08
The cypriot and Iranian National Mutation Frequency Databases. Hum Mutat (2006) 1.08
Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J Immunol (2010) 1.06
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol (2007) 1.05
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther (2005) 1.05
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Dyslipidemia in patients with thyroid disorders. Hormones (Athens) (2006) 1.01
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol (2011) 1.00
Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis (2007) 1.00
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res (2002) 1.00
Oxidative stress markers in laparoscopic versus open colectomy for cancer: a double-blind randomized study. Surg Endosc (2013) 1.00
Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium (2008) 0.99
Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke (2005) 0.99
Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail (2002) 0.97
Correlation of Achilles tendon thickness evaluated by ultrasonography with carotid intima-media thickness in patients with familial hypercholesterolemia. Atherosclerosis (2006) 0.96
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin (2007) 0.96
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids (2008) 0.96
Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol (2005) 0.95
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens (2006) 0.94
Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids (2007) 0.94
Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol (2010) 0.94
Evaluation of alternative calculation methods for determining low-density lipoprotein cholesterol in hemodialysis patients. Clin Biochem (2004) 0.94
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology (2011) 0.94
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol (2002) 0.93
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology (2005) 0.93
C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodial Int (2009) 0.93
The role of obesity in kidney disease: recent findings and potential mechanisms. Int Urol Nephrol (2011) 0.92
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol (2013) 0.92
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther (2007) 0.92
Statin pleiotropy against renal injury. J Cardiometab Syndr (2009) 0.92
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum (2008) 0.92
High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. J Lipid Res (2006) 0.91
Evaluation of tubulointerstitial lesions' severity in patients with glomerulonephritides: an NMR-based metabonomic study. J Proteome Res (2007) 0.91
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther (2006) 0.91
Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther (2007) 0.91
The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids (2006) 0.91
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism (2012) 0.91
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol (2011) 0.90
Severe hyperkalaemia in association with diabetic ketoacidosis in a patient presenting with severe generalized muscle weakness. Nephrol Dial Transplant (2003) 0.90
Effect of Plant Polyphenols on Adipokine Secretion from Human SGBS Adipocytes. Biochem Res Int (2011) 0.90
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin (2006) 0.89
Mononuclear leukocyte apoptosis and inflammatory markers in patients with chronic kidney disease. Am J Nephrol (2012) 0.89
The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol (2008) 0.89
Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. J Neurol Sci (2009) 0.89
Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes (2013) 0.89
Pathophysiology and management of fluid and electrolyte disturbances in patients on chronic dialysis with severe hyperglycemia. Semin Dial (2008) 0.89
Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J Nephrol (2012) 0.88
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother (2011) 0.88
Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. Arch Med Sci (2013) 0.88
Mapping the binding domains of the alpha(IIb) subunit. A study performed on the activated form of the platelet integrin alpha(IIb)beta(3). Eur J Biochem (2003) 0.88
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study. Atherosclerosis (2008) 0.88
Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol (2005) 0.87
Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol (2005) 0.87
The role of statins in chronic kidney disease. Am J Nephrol (2011) 0.87
Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther (2006) 0.87